Low-n oligomers as therapeutic targets of Alzheimer's disease

84Citations
Citations of this article
90Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The pathogenesis of Alzheimer's disease involves the progressive accumulation of amyloid β-protein (Aβ). Recent studies using synthetic Aβ peptides, a cell culture model, Aβ precursor protein transgenic mice models suggest that pre-fibrillar forms of Aβ are more deleterious than extracellular fibril forms. Recent findings obtained using synthetic Aβ peptides and human samples indicated that low-n oligomers (from dimers to octamers) may be proximate toxins for neuron and synapse. Here, we review the recent studies on the soluble oligomers, especially low-n oligomers in Alzheimer's disease. © 2011 The Authors Journal of Neurochemistry © 2011 International Society for Neurochemistry.

Cite

CITATION STYLE

APA

Ono, K., & Yamada, M. (2011, April). Low-n oligomers as therapeutic targets of Alzheimer’s disease. Journal of Neurochemistry. https://doi.org/10.1111/j.1471-4159.2011.07187.x

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free